Greetings readers,

A critical strategy for microbial product development companies is defining the type of microbes they intend to include in their products, specifically whether they will use a single microbe or a microbial consortium ( probiotic consortia) . I strongly advocate for a single microbe per product for several reasons, which I outline below:

1. Limited Understanding of Microbial Interactions: Our knowledge of how microbes interact both in natural environments and controlled settings remains limited. This makes it challenging to predict with confidence how multiple strains in a single product will interact, especially in various target environments.
2. High Costs of Multi-Strain Testing: Conducting trials is costly in any industry. Without regulatory requirements to demonstrate that each strain in a consortium is necessary—and that the product performs differently when any strain is absent—companies are unlikely to invest the resources needed to validate each strain’s role.
3. Lack of Regulatory Efficacy Standards for Consortia: In sectors where consortia-based microbial products are launched, regulations often don’t require efficacy proof for each individual strain or for every possible blend combination. This means there’s no need to confirm that all strains in the consortium are essential for the product’s efficacy, creating questionable outcome for probiotic effectiveness.
4. Quality Oversight Challenges: Consortia may dilute the focus on individual strain quality. When a blend’s specific roles are unclear, it becomes difficult for quality control teams to justify rejecting production batches based on the performance of individual strains. Rejecting batches is costly and time-consuming, and companies may prioritize efficiency over customer benefit, choosing to use all batches to save costs, even if it compromises quality.
5. Reduced Transparency for Customers: For customers, it’s unclear if the efficacy of a consortium-based product stems from individual strains or their interactions. When a product works, customers don’t know if all strains are necessary; if it fails, they’re left guessing which strain or interaction didn’t perform. This lack of transparency makes it harder for consumers to understand what truly drives effectiveness and for their needs what is the most effective probiotic.

For these reasons, I am against using microbial strain blends in a single product. Instead, I focus on selecting a single, carefully chosen strain for each product to ensure quality, efficacy, and transparency

Until next blog, cheers!